West Pharmaceutical Services, Inc. (WST) Financials
Key financial figures for West Pharmaceutical Services, Inc. (Q3 2026).
West raised full-year 2026 guidance after Q3 net sales of $874.5 million (+8.7%, +11.9% organic) and adjusted-diluted EPS of $2.66 (+35.7%), led by HVP Components. Net sales were $874.5 million, up 8.7% from $804.6 million a year earlier; organic growth was 11.9% (excluding currency and the SmartDose 3.5mL transaction). Diluted EPS was $3.02 versus $1.92; adjusted-diluted EPS was $2.66 versus $1.96. Reported operating profit of $267.4 million included a $55.7 million net gain on the sale of the SmartDose 3.5mL On-Body Delivery System assets; adjusted operating profit was $221.5 million (25.3% margin versus 21.1%). On the outlook: Full-year 2026 net sales raised to $3.41 billion to $3.42 billion (previously $3.345 billion to $3.380 billion); organic net sales growth 11.3% to 11.6% (previously 10% to 11%); adjusted-diluted EPS raised to $9.38 to $9.48 (previously $8.85 to $9.05); capital spending lowered to $215 million to $220 million (previously $250 million to $275 million). Figures are for Q3 2026, as West Pharmaceutical Services, Inc. reported them.
- Revenue
- $875M
- Net Income
- $214M
- EPS
- $3.04
- Total Assets
- $4.1B
- Operating Cash Flow
- $190M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q3 FY2026 | $875M | $214M | $3.02 | 30.58% | $150M |
| Q2 FY2026 | $872M | $154M | $2.15 | 20.53% | $81M |
| Q1 FY2026 | $845M | $139M | $1.92 | 20.96% | $47M |
| Q4 FY2025 | $805M | $132M | $1.82 | 19.45% | $175M |
| Q3 FY2025 | $804M | $140M | $1.92 | 21.6% | $134M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $3.1B | $494M | $6.79 | 20.09% | $469M |
| FY2024 | $2.9B | $493M | $6.69 | 20.56% | $276M |
| FY2023 | $3.0B | $593M | $7.88 | 24.09% | $415M |
Frequently asked questions
What was West Pharmaceutical Services, Inc.'s revenue last quarter?
West Pharmaceutical Services, Inc. reported revenue of $874.5 million for Q3 FY2026, up 8.7% from the same period a year earlier.
Is West Pharmaceutical Services, Inc. profitable?
Yes. West Pharmaceutical Services, Inc. reported net income of $214.0 million for Q3 FY2026, a net margin of 24.47% on revenue.
How has West Pharmaceutical Services, Inc.'s margin trended?
Operating margin was 30.58% in Q3 FY2026, compared with 21.6% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did West Pharmaceutical Services, Inc. generate?
West Pharmaceutical Services, Inc. generated free cash flow of $150.4 million in Q3 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for West Pharmaceutical Services, Inc. on SentiSense, with up to forty quarters and twenty fiscal years of history.